Simulations Plus (NASDAQ:SLP) Now Covered by William Blair

William Blair started coverage on shares of Simulations Plus (NASDAQ:SLP) in a research note issued on Friday, Marketbeat Ratings reports. The firm set an “outperform” rating on the technology company’s stock.

Several other research firms have also recently weighed in on SLP. Craig Hallum lifted their price objective on shares of Simulations Plus from $51.00 to $56.00 and gave the stock a “buy” rating in a research report on Thursday, June 13th. Oppenheimer boosted their target price on shares of Simulations Plus from $55.00 to $65.00 and gave the stock an “outperform” rating in a research report on Thursday, June 13th.

Simulations Plus Stock Up 1.5 %

Shares of SLP stock opened at $48.62 on Friday. The business has a 50 day moving average of $47.77 and a two-hundred day moving average of $44.09. The company has a market cap of $971.67 million, a P/E ratio of 91.74 and a beta of 0.75. Simulations Plus has a 52 week low of $32.69 and a 52 week high of $52.69.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings data on Wednesday, April 3rd. The technology company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.02. Simulations Plus had a return on equity of 7.95% and a net margin of 16.22%. The business had revenue of $18.31 million during the quarter, compared to the consensus estimate of $17.31 million. During the same period in the previous year, the firm posted $0.20 earnings per share. The business’s revenue was up 16.2% on a year-over-year basis. Analysts expect that Simulations Plus will post 0.55 EPS for the current fiscal year.

Insider Buying and Selling

In other Simulations Plus news, Director Daniel L. Weiner sold 3,250 shares of the company’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $48.31, for a total transaction of $157,007.50. Following the sale, the director now directly owns 8,759 shares of the company’s stock, valued at $423,147.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $39.94, for a total value of $798,800.00. Following the transaction, the director now directly owns 3,600,195 shares in the company, valued at $143,791,788.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel L. Weiner sold 3,250 shares of the stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $48.31, for a total transaction of $157,007.50. Following the completion of the sale, the director now owns 8,759 shares in the company, valued at $423,147.29. The disclosure for this sale can be found here. Insiders sold 43,750 shares of company stock valued at $1,899,808 over the last quarter. Corporate insiders own 20.90% of the company’s stock.

Institutional Investors Weigh In On Simulations Plus

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Connective Capital Management LLC bought a new position in Simulations Plus in the first quarter valued at $364,000. Kennedy Capital Management LLC grew its position in Simulations Plus by 3.2% in the first quarter. Kennedy Capital Management LLC now owns 229,439 shares of the technology company’s stock valued at $9,441,000 after purchasing an additional 7,077 shares in the last quarter. Silvercrest Asset Management Group LLC bought a new position in Simulations Plus in the first quarter valued at $4,717,000. Public Employees Retirement System of Ohio bought a new position in Simulations Plus in the first quarter valued at $1,082,000. Finally, Price T Rowe Associates Inc. MD grew its position in Simulations Plus by 5.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 10,048 shares of the technology company’s stock valued at $414,000 after purchasing an additional 562 shares in the last quarter. 78.08% of the stock is currently owned by institutional investors and hedge funds.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.